Variability of mycophenolic acid elimination in the renal transplant recipients - population pharmacokinetic approach

被引:13
|
作者
Velickovic-Radovanovic, Radmila M. [1 ,2 ]
Jankovic, Slobodan M. [3 ]
Milovanovic, Jasmina R. [3 ]
Catic-Dordevic, Aleksandra K. [1 ]
Spasic, Ana A. [1 ]
Stefanovic, Nikola Z. [1 ]
Dzodic, Predrag Lj. [1 ]
Smelcerovic, Andrija A. [1 ,4 ]
Cvetkovic, Tatjana P. [2 ,5 ]
机构
[1] Univ Nis, Dept Pharm, Fac Med, Nish 18000, Serbia
[2] Clin Ctr Nis, Clin Nephrol, Nish, Serbia
[3] Univ Kragujevac, Fac Med, Dept Pharmacol & Toxicol, Kragujevac, Serbia
[4] Univ Nis, Fac Med, Dept Chem, Nish 18000, Serbia
[5] Univ Nis, Fac Med, Inst Biochem, Nish 18000, Serbia
关键词
Mycophenolic acid; nonlinear mixed effects model (NONM); population pharmacokinetics; renal transplantation; CLINICAL PHARMACOKINETICS; GLUCURONIDE METABOLITE; PROTEIN-BINDING; MOFETIL; SODIUM; EXPOSURE; TACROLIMUS; PHARMACODYNAMICS; COMPLICATIONS; CYCLOSPORINE;
D O I
10.3109/0886022X.2015.1010442
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The aim of this study was to develop a population pharmacokinetic (PK) model for clearance of mycophenolic acid (MPA) in adult renal transplant recipients, to quantify the PK parameters and the influence of covariates on the MPA pharmacokinetic parameters. Parameters associated with plasma concentrations of MPA at steady-state were analyzed in 70 renal transplant recipients (mean age 42.97 years; mean total body weight 75.33 kg) using nonlinear mixed-effect modeling (NONMEM). Characteristics of patients screened for influence on the pharmacokinetic parameters were gender, age, body weight, time after transplantation, whether the patient was diagnosed as having diabetes mellitus, organ source (living or deceased donor), biochemical parameters and co-therapy (tacrolimus, cyclosporine, prednisolone, omeprazole, bisoprolol, carvedilol, nifedipine). A validation set of 25 renal transplant recipients was used to estimate the predictive performance of population pharmacokinetic model. Typical mean value of MPA oral clearance, estimated by base model (without covariates) was 0.741 L h(-1). During population modeling, the full model showed that clearance of the MPA was significantly influenced by age, total daily dose of MPA, creatinine clearance, albumin level, status and gender of a donor, and the nifedipine and tacrolimus co-therapy. In the final model, clearance of MPA was reported to be significantly influenced by age, total daily dose of MPA and thenifedipine co-therapy. The derived model describes adequately MPA clearance in terms of characteristics of our patients, offering basis for individual pharmacotherapy approach.
引用
收藏
页码:652 / 658
页数:7
相关论文
共 50 条
  • [21] Monitoring of mycophenolic acid in pediatric renal transplant recipients
    Armstrong, VW
    Shipkova, M
    Schütz, E
    Weber, L
    Tönshoff, B
    Oellerich, M
    TRANSPLANTATION PROCEEDINGS, 2001, 33 (1-2) : 1040 - 1043
  • [22] Genetics partly explains patient variability of mycophenolic acid pharmacokinetics in renal transplant recipients.
    Baldelli, Sara
    Merlini, Simona
    Nicastri, Annalisa
    Bertolini, Barbara
    Perico, Norberto
    Remuzzi, Giuseppe
    Cattaneo, Dario
    AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 : 184 - 184
  • [23] Pharmacokinetic variability of sirolimus in Taiwanese renal transplant recipients
    Chueh, SCJ
    Wang, SM
    Lai, MK
    Chen, J
    TRANSPLANTATION PROCEEDINGS, 2004, 36 (07) : 2058 - 2059
  • [24] The variability in pharmacokinetic profiles of mycophenolic acid after renal transplantation
    Zdrojewski, Z
    Wolyniec, W
    Debska-Slizien, A
    Chamienia, A
    Rutkowski, B
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 362A - 362A
  • [25] Population pharmacokinetic modeling for mycophenolic acid and its main glucuronide metabolite in Chinese kidney transplant recipients
    YANG Chun-lan
    SHENG Chang-cheng
    FENG Li-juan
    JIAO Zheng
    XU Du-juan
    中国药理学与毒理学杂志, 2019, (10) : 817 - 817
  • [26] Therapeutic drug monitoring of mycophenolic acid in renal transplant recipients
    Okamoto, M
    Wakabayashi, Y
    Higuchi, A
    Kadotani, Y
    Ogino, S
    Ushigome, H
    Akioka, K
    Kaihara, S
    Yoshimura, N
    TRANSPLANTATION PROCEEDINGS, 2005, 37 (02) : 859 - 860
  • [27] Plasma level monitoring of mycophenolic acid in renal transplant recipients
    Sarangi, S. C.
    Reeta, K. H.
    Agarwal, S. K.
    Guleria, S.
    Gupta, Y. K.
    INDIAN JOURNAL OF PHARMACOLOGY, 2008, 40 : 52 - 52
  • [28] Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in Chinese adult renal transplant recipients
    Zi-cheng Yu
    Pei-jun Zhou
    Xiang-hui Wang
    Bressolle Françoise
    Da Xu
    Wei-xia Zhang
    Bing Chen
    Acta Pharmacologica Sinica, 2017, 38 : 1566 - 1579
  • [29] Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in Chinese adult renal transplant recipients
    Yu, Zi-cheng
    Zhou, Pei-jun
    Wang, Xiang-hui
    Francoise, Bressolle
    Xu, Da
    Zhang, Wei-xia
    Chen, Bing
    ACTA PHARMACOLOGICA SINICA, 2017, 38 (11) : 1566 - 1579
  • [30] Adverse effects of mycophenolic acid in renal transplant recipients: gender differences
    Ana Spasić
    Aleksandra Catić-Đorđević
    Radmila Veličković-Radovanović
    Nikola Stefanović
    Predrag Džodić
    Tatjana Cvetković
    International Journal of Clinical Pharmacy, 2019, 41 : 776 - 784